Written questions by Hunt.

What progress he has made on implementing the recommendations of the report Reading the Signals: Maternity and Neonatal Services in East Kent since its publication.

Awaiting answer.

What progress he has made on implementing the 15 Immediate and Essential Actions set out in the final report of the Ockenden Review into maternity services at the Shrewsbury and Telford Hospital NHS Trust.

Awaiting answer.

What assessment he has made of the Mann Review (March 2026) as potential justification for retaining the General Medical Council’s section 40A appeal power in the Draft Order.

All of the proposals relating to the findings of the Williams Review and the Mann Review contained within the Reforming the General Medical Council legislative framework consultation, published 24 March 2026, are currently open for public consultation. We welcome stakeholder views on the consultation and responses will be carefully considered to help inform future policy decisions.

Whether his Department continues to support Recommendation 6.1 of the Williams Review on removing the General Medical Council’s right of appeal under section 40A of the Medical Act 1983.

All of the proposals relating to the findings of the Williams Review and the Mann Review contained within the Reforming the General Medical Council legislative framework consultation, published 24 March 2026, are currently open for public consultation. We welcome stakeholder views on the consultation and responses will be carefully considered to help inform future policy decisions.

What progress his Department has made on (a) developing and (b) publishing a national implementation plan for Fracture Liaison Services.

Our 10-Year Health Plan committed to rolling out Fracture Liaison Services across every part of the country by 2030. Integrated care boards (ICBs) remain well-placed to make decisions according to local need. The Renewed Women’s Health Strategy sets an expectation that ICBs prioritise community-based models when commissioning new fracture prevention services.

If he will require that healthcare professionals involved in the care of people with very severe ME complete condition-specific (a) training and (b) e-learning.

NHS England, with support from the Department, has developed an e-learning programme to support healthcare professionals in the care of people with myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), of all levels of severity. All four sessions of the e-learning programme are now available, with sessions one, two, and three having universal access, whilst the fourth session, which includes support and clinical management of severe ME/CFS, is only available to healthcare professionals. Further information can be found at the following link:https://learninghub.nhs.uk/catalogue/mecfselearning?nodeId=7288The Medical Schools Council will promote the e-learning programme to all United Kingdom medical schools and will encourage those medical schools to provide undergraduates with direct patient experience of ME/CFS.Additionally, the National Institute for Health and Care Excellence (NICE) has developed guidance on the diagnosis and management of ME/CFS, including mental health support for people with ME/CFS and their families. NICE guidelines are evidence-based, informed by clinical expertise, and represent best practice, and although NICE guidelines are not mandatory, healthcare professionals are expected to take them fully into account.

What assessment his Department has made of trends in the (a) prevalence of respiratory disease and (b) number of emergency hospital admissions for respiratory conditions in Godalming and Ash constituency compared with national averages.

Data is available for emergency Finished Admission Episodes (FAEs) where there was a primary diagnosis of 'respiratory conditions’. The following table shows the number of FAEs where there was a primary diagnosis of 'respiratory conditions’ for Godalming and Ash and England, for activity in English National Health Service hospitals and English NHS commissioned activity in the independent sector, for 2024/25 and provisionally for 2025/26:Westminster Parliamentary Constituency of Residence2024/25 (August 2024 to March 2025)2025/26 (April 2025 to November 2025)Godalming and Ash935775England612,855511,558Source: Hospital Episode Statistics, NHS England. Available data on trends in respiratory conditions can be found on the Department’s Fingertips dataset. Data is not available by parliamentary constituency. Data is available at regional, county, unitary authority, and integrated care board level. Information for Surrey, which includes Godalming and Ash, can be found at the following link: https://fingertips.phe.org.uk/search/Respiratory#page/1/gid/1/pat/15/ati/502/are/E10000030/iid/40701/age/163/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1

How the functions of local Healthwatch will be delivered by ICBs and local authorities.

The abolition of local Healthwatch (LHW) and the transfer of its functions will require primary legislation. The timing of this is subject to the will of Parliament and will happen when parliamentary time allows.We are proposing to place responsibility for the health function of LHW with integrated care boards. Local authorities will be responsible for the social care LHW functions.

What steps she is taking to help improve the global competitiveness of the City of London.

The government’s Financial Services Growth and Competitiveness Strategy , co-designed with industry, sets out the government’s ten-year plan to make the UK the world’s centre of choice for financial services investment now and in 2035. Since July, the Government has been squarely focused on delivery the Strategy, including launching the Office for Investment: Financial Services to attract and support global firms to establish and grow in the UK and UK listings relief – exempting shares from Stamp Duty Reserve Tax for the first three years that a company is listed.The government will continue working at pace to deliver the reforms it has committed to.

When he plans to respond to emails sent by the Rt Hon. Member for Godalming and Ash dated 18 November 2025 and 20 January 2026 concerning a case relating to a Magistrate.

A response was sent on 24 February and the Department apologises for the significant delay in replying. We recognise that, on this occasion, the delay falls short of expected standards.

What steps he is taking to ensure that Cystic Fibrosis patients living in North London are not adversely impacted by the proposed removal of respiratory services from the Royal Brompton Hospital.

Any changes to services must follow established statutory processes, including full clinical engagement, consideration of patient impact, and public consultation where required. These processes are designed to ensure that any proposed reconfiguration maintains or improves the quality, safety, and accessibility of care for patients.The Department expects NHS England and local commissioners to demonstrate that any changes will not adversely affect patients with cystic fibrosis (CF) and that services continue to meet the national service specifications for specialised respiratory and CF care. This includes ensuring that specialist multidisciplinary CF teams remain accessible, that transition and continuity of care are safeguarded, and that travel times and capacity implications are assessed and mitigated.Although the location of some services will change, there is no reduction in CF services capacity and no loss of specialist expertise as a result of this change. The full paediatric CF multidisciplinary team, including specialist clinicians, nurses, physiotherapists, psychologists and dietitians, will continue to care for patients as a single specialist service.

What steps he is taking to ensure that patients with suspected endometriosis can access clinicians with specialist expertise through the NHS online hospital.

NHS Online will be a new, optional online service allowing patients to digitally connect with clinicians across England. In January 2026, we announced the initial specialities and conditions that NHS Online will focus on. Menstrual problems that may be a sign of endometriosis will be one of the first conditions available for referral to NHS Online when it launches in 2027. This pathway being developed for NHS Online incorporates a process for investigation, management, and onward referral to specialist services within a timely manner if clinically indicated.This means that when a patient goes to see their general practitioner, they will have the option of being referred, through their legal right to choice, to NHS Online for their care. Should a consultation be required, they will see the next available specialist, who may be anywhere in the country. Following an NHS Online assessment, if a patient requires or chooses a face-to-face consultation they will be referred to a local provider.Patient safety will not be compromised. Clinical oversight will be robust, keeping patient safety at the heart of the process.

What steps he is taking to ensure that women accessing care for (a) menopause and (b) menstrual disorders via the NHS online hospital can be referred efficiently to in-person specialist services when needed.

NHS Online will be a new, optional online service allowing patients to digitally connect with clinicians across England. When a patient is referred to NHS Online, should a consultation be required, they will see the next available specialist, who may be anywhere in the country. For patients who are diagnosed with menopause or menstrual disorders conditions, where the NHS Online clinician determines that in-person specialist services are the appropriate treatment, they will be transferred to appropriate local services, including in-person specialist care.Patients will always have the choice of face-to-face appointments, and those who need physical examinations or procedures will continue to receive them either at hospital or local hubs nearby. If a patient displays more complex symptoms after the original referral to NHS Online, then they can be referred back on to a more traditional pathway.

What estimate his Department has made of the workforce required to provide specialist women’s health services through the NHS online hospital.

Analysis shows that the anticipated workforce available to provide women’s health services through the NHS online hospital, provides enough capacity to meet the demand for the service in the first three years.

What assessment he has made of the potential impact of the NHS online hospital on women’s health inequalities.

Women’s health issues, including severe menopause symptoms and menstrual problems that may be a sign of endometriosis, fibroids, polycystic ovary syndrome, adenomyosis, or pelvic infection, will be among the conditions available for referral to NHS Online from 2027.NHS Online will be unconstrained by geographical boundaries, able to better align clinical capacity with patient demand, and will help tackle deep rooted inequalities in the healthcare system by ending the postcode lottery of care and waiting times, including for women’s health issues. Once referred by their general practitioner, patients can be seen quickly by National Health Service specialists online. Remote consultations, follow-ups, and condition management can be delivered digitally. Streamlined pathways will shorten delays between referral and treatment and help patients start their care sooner.NHS Online will help to reduce patient waiting times, delivering the equivalent of up to 8.5 million appointments and assessments in its first three years, four times more than an average trust, while enhancing patient choice and control over their care.NHS Online is undertaking a detailed equality health impact assessment to assess the impacts of the service, and is working with patients and carers to ensure that these are addressed. Patient choice remains central to care. NHS Online will enhance patient choice with in-person care always available for those who prefer and for those whose care needs require it.Before NHS Online goes live, the NHS will learn from existing research on patient experience of online care over the last five years and build it into the programme as it develops. The programme is being developed with a commitment to patient partnership in design and delivery. We will be working with marginalised groups, including through the Voluntary, Community, and Social Enterprise sector, which represents communities who share protected characteristics or that experience health inequalities, with further information available at the following link:https://www.england.nhs.uk/hwalliance/Inclusion will be a core priority as the organisation evolves.

What assessment his Department has made of the potential impact of the NHS online hospital on levels of regional variation in gynaecology waiting times.

Women’s health issues, including severe menopause symptoms and menstrual problems that may be a sign of endometriosis, fibroids, polycystic ovary syndrome, adenomyosis, or pelvic infection, will be among the conditions available for referral to NHS Online from 2027.NHS Online will be unconstrained by geographical boundaries, able to better align clinical capacity with patient demand, and will help tackle deep rooted inequalities in the healthcare system by ending the postcode lottery of care and waiting times, including for women’s health issues. Once referred by their general practitioner, patients can be seen quickly by National Health Service specialists online. Remote consultations, follow-ups, and condition management can be delivered digitally. Streamlined pathways will shorten delays between referral and treatment and help patients start their care sooner.NHS Online will help to reduce patient waiting times, delivering the equivalent of up to 8.5 million appointments and assessments in its first three years, four times more than an average trust, while enhancing patient choice and control over their care.NHS Online is undertaking a detailed equality health impact assessment to assess the impacts of the service, and is working with patients and carers to ensure that these are addressed. Patient choice remains central to care. NHS Online will enhance patient choice with in-person care always available for those who prefer and for those whose care needs require it.Before NHS Online goes live, the NHS will learn from existing research on patient experience of online care over the last five years and build it into the programme as it develops. The programme is being developed with a commitment to patient partnership in design and delivery. We will be working with marginalised groups, including through the Voluntary, Community, and Social Enterprise sector, which represents communities who share protected characteristics or that experience health inequalities, with further information available at the following link:https://www.england.nhs.uk/hwalliance/Inclusion will be a core priority as the organisation evolves.

What steps his Department is taking to improve access to clinical trials for patients with pancreatic cancer.

The Department is committed to ensuring that all patients, including those with pancreatic cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.The Department funds research and research infrastructure through the National Institute for Health and Care Research (NIHR), which supports National Health Service patients, the public, and NHS organisations across England to participate in high-quality research, including clinical trials into cancers.NIHR provides an online service called 'Be Part of Research', which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest.The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials.The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials, on for example pancreatic cancer, to take place in England, by ensuring the patient population can be more easily contacted by researchers.

What steps he is taking to (a) prioritise research into pancreatic cancer and (b) encourage innovations in earlier diagnosis.

The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR), and in 2024/25, spent £141.6 million on cancer research, signalling its high priority. This includes studies that focus specifically on pancreatic cancer as well as studies that are relevant to or include pancreatic cancer. For example, between the 2020/21 to 2024/25 financial years, the NIHR committed £1.5 million to specific pancreatic cancer studies.One instance of this is ongoing research funded by the NIHR which aims into improve the early diagnosis of pancreatic cancer by utilising artificial intelligence as well as reducing instances of missed cancer.The NIHR’s wider investments in research infrastructure, including facilities, services, and the research workforce, supported the delivery of 160 pancreatic cancer research studies and enabled over 8,200 people to participate in potentially life-changing research during this time period. This includes support for the PemOla trial, which is the first to explore using precision immunotherapies to treat pancreatic cancer.The Office for Life Sciences’ Cancer Healthcare Goals programme aims to maximise and direct global industrial investment for the development and acceleration of new cancer diagnostic and therapeutic technologies and devices in the United Kingdom through: providing research investments to support the development of innovations in the early stages of the development pathway and; supporting industry to accelerate cancer diagnostic and therapeutic technologies and devices in the latter stages of development into the National Health Service.The programme launched the £10.9 million NIHR i4i Cancer Healthcare Goals: Early Cancer Diagnosis Clinical Validation and Evaluation Call. This has funded six projects which are developing breakthrough technologies that can increase the proportion of cancers which are detected earlier in the disease course and/or target health inequalities in cancer diagnosis.This includes the miONCO-Dx multi-cancer early detection test, developed by XGenera, which can identify 12 of the most lethal and common cancers, including pancreatic cancer, at even the earliest stages from just 100 microlitres of blood. This technology is currently testing the diagnostic test accuracy on over 20,000 patient samples with promising early results.The NIHR continues to encourage and welcome high quality funding applications into pancreatic cancer.

When he plans to publish the report into the cost of clinical negligence being prepared by David Lock KC.

The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.As announced in the 10-Year Health Plan for England, David Lock KC is providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims. The review is ongoing, following initial advice to ministers and the recent National Audit Office’s report.The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.

If she will support the proposal made by the Netherlands government to amend the shoulder height requirements in regulation R129 at the upcoming 77th meeting of the UN Working Party on Passive Safety in Geneva in December.

The Department for Transport noted the informal document presented by the Kingdom of the Netherlands to the 77th meeting of the UNECE Working Party on Passive Safety (GRSP) in May 2025 to amend Regulation 129 on Child Restraint Systems. An associated working document was published on 23 September for the 78th meeting of GRSP in December. The Government treats road safety seriously and is committed to reducing the numbers of those killed and injured on our roads. Where there is clear evidence of a substantial safety issue related to the design of vehicle accessories, the Department will consider positively the evolution of international regulations and will assess this proposal carefully in advance of the next meeting of GRSP.